Minerva Neurosciences, Inc
Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $2.16
- 52-Week Range
- $1.96 – $8.80
- Market Cap
- $108.64M
- P/E (TTM)
- —
- EPS (TTM)
- -33.83
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- —
- PEG Ratio
- —
- Return on Equity
- —
- Return on Assets
- -34.75%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 33.02
- Debt/Equity
- —
- Total Debt
- $60.00M
- Free Cash Flow
- $-13.18M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $103.44M
Market Snapshot
About
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders. The company focuses on treatments for schizophrenia, insomnia, depression, and Parkinson disease.